ClinicalTrials.gg
CompletedNCT00873483Updated Apr 8, 2021

US Ovulation Inhibition Study in Obese Women

A Phase 2 interventional study of Ethinylestradiol/Gestodene (BAY86-5016) in Contraception, sponsored by Bayer. Completed at 6 sites in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-08.

Sponsored by Bayer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
173
Allocation
Non-randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

Birth Control Patch Study

02

Conditions studied

  • Contraception

Keywords

  • Pregnancy prevention
  • female contraception
  • patch
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subject requesting
  • Age: 18 - 35 years (inclusive); smokers must not be older than 30 years at the time of
  • Normal cervical smear not requiring further follow-up (a cervical smear has to be taken at screening visit or a normal result has to be documented within the previous 6 months)
  • History of regular cyclic menstrual periods
  • Willingness to use non-hormonal methods of contraception during the entire study.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation (less than 3 menstrual cycles since delivery, abortion, or lactation before start of treatment)
  • to any ingredient of the study drug
  • Significant skin reaction to transdermal preparations or sensitivity to surgical/medical tape
  • Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug (e.g., known skin disease with suspected alteration of dermal absorption or poor adherence of the patch such as psoriasis)
  • Any disease or condition that may worsen under hormonal treatment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
173 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Ethinylestradiol/Gestodene (BAY86-5016)

Interventions

  • DrugEthinylestradiol/Gestodene (BAY86-5016)

    Drug pages: Ethinyl Estradiol · Gestodene

    0.55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 3 cycles

06

What researchers measure

Primary outcomes

  1. Determination of Hoogland Scores

    Time frame: Treatment Cycles 2 & 3

Secondary outcomes

  1. Laboratory values for E2, progesterone, FSH and LH

    Time frame: Pretreatment & regularly during Treatment Cycles 1, 2, 3

  2. Endometrial thickness

    Time frame: Pretreatment & regularly during Treatment Cycles 1, 2, 3

  3. Follicle size

    Time frame: Pretreatment & regularly during Treatment Cycles 1, 2, 3

07

Study locations

6 sites
  • Tucson, Arizona 85712, United States
  • San Diego, California 92108, United States
  • Sandy Springs, Georgia 30328, United States
  • Philadelphia, Pennsylvania 19114, United States
  • Houston, Texas 77054, United States
  • Seattle, Washington 98105, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2009 to primary completion in Mar 2010, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2009
First posted
Apr 1, 2009
StartActual
Apr 30, 2009
Primary completionActual
Mar 3, 2010
CompletionActual
Mar 3, 2010
Last update
Apr 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00873483
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 1, 2009
Start date
Apr 30, 2009
Primary completion
Mar 3, 2010
Completion
Mar 3, 2010
Last update
Apr 8, 2021

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ethinyl Estradiol · Gestodene

Start the discussion